Listed

Compass Therapeutics, Inc.

CMPXNasdaqCIK 1738021HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q4 FY2025
Operating income−$27.0m, Q2 FY2026
Net income−$25.2m, Q2 FY2026
Compass Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m0.0Revenue, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2024-11-12, accession 0001171843-24-006248.Report this figure0.0Revenue, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2025-02-27, accession 0001171843-25-001106. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.9Revenue, Q2 FY2024, three months to 2024-06-30$850.0k. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure0.0Revenue, Q3 FY2024, three months to 2024-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure0.0Revenue, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figurenot reported0.0Revenue, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure0.0Revenue, Q3 FY2025, three months to 2025-09-30$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure0.0Revenue, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported
Research and development$mnot reportednot reported9.5Research and development, Q1 FY2024, three months to 2024-03-31$9.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure11.2Research and development, Q2 FY2024, three months to 2024-06-30$11.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure8.6Research and development, Q3 FY2024, three months to 2024-09-30$8.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure13.0Research and development, Q4 FY2024, three months to 2024-12-31$13.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure13.1Research and development, Q1 FY2025, three months to 2025-03-31$13.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure16.4Research and development, Q2 FY2025, three months to 2025-06-30$16.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure12.8Research and development, Q3 FY2025, three months to 2025-09-30$12.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure13.7Research and development, Q4 FY2025, three months to 2025-12-31$13.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure13.4Research and development, Q1 FY2026, three months to 2026-03-31$13.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figurenot reported
Operating income$m(11.9)Operating income, Q3 FY2023, three months to 2023-09-30−$11.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-12, accession 0001171843-24-006248.Report this figure(15.4)Operating income, Q4 FY2023, three months to 2023-12-31−$15.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0001171843-25-001106. Derived: 12-month figure less the 9-month figure.Report this figure(12.8)Operating income, Q1 FY2024, three months to 2024-03-31−$12.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure(15.0)Operating income, Q2 FY2024, three months to 2024-06-30−$15.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure(12.2)Operating income, Q3 FY2024, three months to 2024-09-30−$12.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure(16.6)Operating income, Q4 FY2024, three months to 2024-12-31−$16.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure(18.0)Operating income, Q1 FY2025, three months to 2025-03-31−$18.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure(21.1)Operating income, Q2 FY2025, three months to 2025-06-30−$21.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure(15.8)Operating income, Q3 FY2025, three months to 2025-09-30−$15.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure(18.0)Operating income, Q4 FY2025, three months to 2025-12-31−$18.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure(20.3)Operating income, Q1 FY2026, three months to 2026-03-31−$20.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure(27.0)Operating income, Q2 FY2026, three months to 2026-06-30−$27.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2023-11-09, accession 0001171843-23-006912.Report this figure0.0Income tax, Q4 FY2023, three months to 2023-12-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-02-27, accession 0001171843-25-001106. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-08-12, accession 0001171843-24-004670.Report this figurenot reportednot reported0.0Income tax, Q1 FY2025, three months to 2025-03-31$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figurenot reportednot reportednot reportednot reportednot reported
Net income$m(10.0)Net income, Q3 FY2023, three months to 2023-09-30−$10.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-12, accession 0001171843-24-006248.Report this figure(13.4)Net income, Q4 FY2023, three months to 2023-12-31−$13.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0001171843-25-001106. Derived: 12-month figure less the 9-month figure.Report this figure(10.8)Net income, Q1 FY2024, three months to 2024-03-31−$10.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure(13.1)Net income, Q2 FY2024, three months to 2024-06-30−$13.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure(10.5)Net income, Q3 FY2024, three months to 2024-09-30−$10.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure(15.0)Net income, Q4 FY2024, three months to 2024-12-31−$15.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure(16.6)Net income, Q1 FY2025, three months to 2025-03-31−$16.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure(19.9)Net income, Q2 FY2025, three months to 2025-06-30−$19.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure(14.3)Net income, Q3 FY2025, three months to 2025-09-30−$14.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure(15.7)Net income, Q4 FY2025, three months to 2025-12-31−$15.7m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure(18.3)Net income, Q1 FY2026, three months to 2026-03-31−$18.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure(25.2)Net income, Q2 FY2026, three months to 2026-06-30−$25.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure
Diluted EPS$ per sharenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Basic EPS$ per share(0.08)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-12, accession 0001171843-24-006248.Report this figurenot reported(0.08)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure(0.10)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure(0.08)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figurenot reported(0.12)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure(0.14)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.14 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure(0.08)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.08 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figurenot reported(0.10)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure(0.13)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure

Balance sheet

Cash and equivalents$35.5m, Q2 FY2026
Shareholders' equity$166.0m, Q2 FY2026
Compass Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m30.4Cash and equivalents, Q3 FY2023, at 2023-09-30$30.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-09, accession 0001171843-23-006912.Report this figure24.2Cash and equivalents, FY2023, at 2023-12-31$24.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-27, accession 0001171843-25-001106.Report this figure43.5Cash and equivalents, Q1 FY2024, at 2024-03-31$43.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure19.4Cash and equivalents, Q2 FY2024, at 2024-06-30$19.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure19.4Cash and equivalents, Q3 FY2024, at 2024-09-30$19.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure43.5Cash and equivalents, FY2024, at 2024-12-31$43.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-05, accession 0001171843-26-001337.Report this figure41.0Cash and equivalents, Q1 FY2025, at 2025-03-31$41.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure22.9Cash and equivalents, Q2 FY2025, at 2025-06-30$22.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure46.2Cash and equivalents, Q3 FY2025, at 2025-09-30$46.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure30.6Cash and equivalents, FY2025, at 2025-12-31$30.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure55.2Cash and equivalents, Q1 FY2026, at 2026-03-31$55.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure35.5Cash and equivalents, Q2 FY2026, at 2026-06-30$35.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure
Current assets$m167Current assets, Q3 FY2023, at 2023-09-30$166.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0001171843-23-006912.Report this figure154Current assets, FY2023, at 2023-12-31$153.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0001171843-25-001106.Report this figure159Current assets, Q1 FY2024, at 2024-03-31$158.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-13, accession 0001171843-24-002785.Report this figure154Current assets, Q2 FY2024, at 2024-06-30$153.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-12, accession 0001171843-24-004670.Report this figure141Current assets, Q3 FY2024, at 2024-09-30$141.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-12, accession 0001171843-24-006248.Report this figure133Current assets, FY2024, at 2024-12-31$132.8m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-05, accession 0001171843-26-001337.Report this figure124Current assets, Q1 FY2025, at 2025-03-31$124.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure106Current assets, Q2 FY2025, at 2025-06-30$106.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure221Current assets, Q3 FY2025, at 2025-09-30$221.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure210Current assets, FY2025, at 2025-12-31$209.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure196Current assets, Q1 FY2026, at 2026-03-31$195.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure181Current assets, Q2 FY2026, at 2026-06-30$180.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure
Total assets$m170Total assets, Q3 FY2023, at 2023-09-30$170.0m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0001171843-23-006912.Report this figure157Total assets, FY2023, at 2023-12-31$156.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0001171843-25-001106.Report this figure161Total assets, Q1 FY2024, at 2024-03-31$161.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-13, accession 0001171843-24-002785.Report this figure156Total assets, Q2 FY2024, at 2024-06-30$155.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-12, accession 0001171843-24-004670.Report this figure149Total assets, Q3 FY2024, at 2024-09-30$149.2m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-12, accession 0001171843-24-006248.Report this figure140Total assets, FY2024, at 2024-12-31$140.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-05, accession 0001171843-26-001337.Report this figure131Total assets, Q1 FY2025, at 2025-03-31$131.5m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure117Total assets, Q2 FY2025, at 2025-06-30$116.7m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure231Total assets, Q3 FY2025, at 2025-09-30$231.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure220Total assets, FY2025, at 2025-12-31$219.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure205Total assets, Q1 FY2026, at 2026-03-31$205.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure190Total assets, Q2 FY2026, at 2026-06-30$190.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure
Current liabilities$m9.1Current liabilities, Q3 FY2023, at 2023-09-30$9.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0001171843-23-006912.Report this figure7.8Current liabilities, FY2023, at 2023-12-31$7.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0001171843-25-001106.Report this figure3.9Current liabilities, Q1 FY2024, at 2024-03-31$3.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-13, accession 0001171843-24-002785.Report this figure9.5Current liabilities, Q2 FY2024, at 2024-06-30$9.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-12, accession 0001171843-24-004670.Report this figure4.4Current liabilities, Q3 FY2024, at 2024-09-30$4.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-12, accession 0001171843-24-006248.Report this figure8.9Current liabilities, FY2024, at 2024-12-31$8.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-05, accession 0001171843-26-001337.Report this figure14.9Current liabilities, Q1 FY2025, at 2025-03-31$14.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure13.9Current liabilities, Q2 FY2025, at 2025-06-30$13.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure12.4Current liabilities, Q3 FY2025, at 2025-09-30$12.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure14.0Current liabilities, FY2025, at 2025-12-31$14.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure10.3Current liabilities, Q1 FY2026, at 2026-03-31$10.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure16.1Current liabilities, Q2 FY2026, at 2026-06-30$16.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure
Total liabilities$m10.0Total liabilities, Q3 FY2023, at 2023-09-30$10.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0001171843-23-006912.Report this figure8.3Total liabilities, FY2023, at 2023-12-31$8.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0001171843-25-001106.Report this figure4.1Total liabilities, Q1 FY2024, at 2024-03-31$4.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-13, accession 0001171843-24-002785.Report this figure9.5Total liabilities, Q2 FY2024, at 2024-06-30$9.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-12, accession 0001171843-24-004670.Report this figure10.8Total liabilities, Q3 FY2024, at 2024-09-30$10.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-12, accession 0001171843-24-006248.Report this figure15.2Total liabilities, FY2024, at 2024-12-31$15.2m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-05, accession 0001171843-26-001337.Report this figure21.2Total liabilities, Q1 FY2025, at 2025-03-31$21.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure23.5Total liabilities, Q2 FY2025, at 2025-06-30$23.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0001171843-25-005261.Report this figure21.6Total liabilities, Q3 FY2025, at 2025-09-30$21.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure22.8Total liabilities, FY2025, at 2025-12-31$22.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure18.7Total liabilities, Q1 FY2026, at 2026-03-31$18.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure24.1Total liabilities, Q2 FY2026, at 2026-06-30$24.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure
Long-term debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m160Shareholders' equity, Q3 FY2023, at 2023-09-30$160.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-12, accession 0001171843-24-006248.Report this figure149Shareholders' equity, FY2023, at 2023-12-31$148.5m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-05, accession 0001171843-26-001337.Report this figure157Shareholders' equity, Q1 FY2024, at 2024-03-31$157.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure146Shareholders' equity, Q2 FY2024, at 2024-06-30$146.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure138Shareholders' equity, Q3 FY2024, at 2024-09-30$138.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure125Shareholders' equity, FY2024, at 2024-12-31$125.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure110Shareholders' equity, Q1 FY2025, at 2025-03-31$110.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure93.2Shareholders' equity, Q2 FY2025, at 2025-06-30$93.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure210Shareholders' equity, Q3 FY2025, at 2025-09-30$209.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure197Shareholders' equity, FY2025, at 2025-12-31$196.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure186Shareholders' equity, Q1 FY2026, at 2026-03-31$186.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure166Shareholders' equity, Q2 FY2026, at 2026-06-30$166.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure

Cash flow

Operating cash flow−$14.7m, Q2 FY2026
Capital expenditure$176.0k, Q2 FY2026
Compass Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(5.9)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$5.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-12, accession 0001171843-24-006248. Derived: 9-month figure less the 6-month figure.Report this figure(12.4)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$12.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001171843-25-001106. Derived: 12-month figure less the 9-month figure.Report this figure(13.9)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$13.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure(10.8)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$10.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0001171843-25-005261. Derived: 6-month figure less the 3-month figure.Report this figure(11.1)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$11.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001171843-25-007005. Derived: 9-month figure less the 6-month figure.Report this figure(9.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$9.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure(13.2)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$13.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure(11.8)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$11.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001171843-26-005295. Derived: 6-month figure less the 3-month figure.Report this figure(10.8)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$10.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-05, accession 0001171843-25-007005. Derived: 9-month figure less the 6-month figure.Report this figure(13.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$13.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure(17.3)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$17.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure(14.7)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$14.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001171843-26-005295. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$10.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-12, accession 0001171843-24-006248. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$9.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001171843-25-001106. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0001171843-25-002953.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0001171843-25-005261. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$44.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001171843-25-007005. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2025, three months to 2025-03-31$18.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure0.0Capital expenditure, Q2 FY2025, three months to 2025-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001171843-26-005295. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$7.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-05, accession 0001171843-25-007005. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-05, accession 0001171843-26-001337. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$82.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure0.2Capital expenditure, Q2 FY2026, three months to 2026-06-30$176.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001171843-26-005295. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)138.20m, Q1 FY2025
Compass Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20242024-09-30Q1 FY20252025-03-31
Diluted shares (weighted)m shares138Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30137,600,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-05, accession 0001171843-25-007005.Report this figure138Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31138,200,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-05, accession 0001171843-26-003006.Report this figure

Shares outstanding: 180.09mShares outstanding, period not labelled, at 2026-07-28180,087,915 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001171843-26-005295.Report this figure at Jul 28, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. Listed shows no prices and gives no investment advice.